Transgenomic has appointed Matthew Beer as vice president of business development for oncology; and John McAuliffe as vice president of business development for neurology.
Beer was previously director of oncology marketing and hematology/oncology life cycle leader at Quest Diagnostics. Prior to that, he was vice president of business development at Caris Life Sciences. He has also worked for Abbott, Targeted Molecular Diagnostics, and Oncotech. He holds a BS in microbiology from the University of Iowa.